Metformin (hydrochloride)
CAT:
804-HY-17471A-01
Size:
5 mg
For Laboratory Research Only. Not for Clinical or Personal Use.
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Metformin (hydrochloride)
UNSPSC Description:
Metformin hydrochloride (1,1-Dimethylbiguanide hydrochloride) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin hydrochloride triggers autophagy[1].Target Antigen:
AMPK; Autophagy; MitophagyType:
Reference compoundRelated Pathways:
Autophagy;Epigenetics;PI3K/Akt/mTORApplications:
Cancer-Kinase/proteaseField of Research:
Metabolic Disease; Cardiovascular Disease; CancerAssay Protocol:
https://www.medchemexpress.com/Metformin-hydrochloride.htmlSolubility:
DMSO : ≥ 1.7 mg/mL|H2O : ≥ 100 mg/mLSmiles:
NC(NC(N(C)C)=N)=N.ClMolecular Weight:
165.62References & Citations:
[1]Soraya H, et al. Acute treatment with metformin improves cardiac function following NSC 37745 induced myocardial infarction in rats. Pharmacol Rep. 2012;64(6):1476-84.|[2]Xue J, et al. Metformin inhibits growth of eutopic stromal cells from adenomyotic endometrium via AMPK activation and subsequent inhibition of AKT phosphorylation: a possible role in the treatment of adenomyosis. Reproduction. 2013 Aug 21;146(4):397-406.|[3]Otto M, et al. Metformin inhibits glycogen synthesis and gluconeogenesis in cultured rat hepatocytes. Diabetes Obes Metab. 2003 May;5(3):189-94.|[4]Avci CB, et al. Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. Asian Pac J Cancer Prev. 2013;14(2):765-8.Acta Biochim Biophys Sin. 2021 Feb 1;gmaa180.|Adv Mater. 2020 Nov;32(45):e2003708.|Andrology. 2020 May;8(3):663-670.|Arch Toxicol. 2019 Jun;93(6):1697-1712. |Biochem Pharmacol. 2017 Aug 15;138:49-60. |Biomaterials. 2021 Jul;274:120850.|Biomed Pharmacother. 2019 Jul;115:108875.|Biomed Pharmacother. 2024 Sep 6:179:117399.|Bone Res. 2023 Aug 16;11(1):45.|Brain Res Bull. 2020 Nov;164:146-156.|Cancer Cell. 2020 Sep 14;38(3):350-365.e7.|Cancers (Basel). 2021 Aug 6;13(16):3978.|Cancers (Basel). 2022 Mar 17;14(6):1538.|Cell Death Dis. 2021 Oct 2;12(10):902.|Cell Death Dis. 2021 Oct 9;12(10):925.|Cell Metab. 2023 Jan 3;35(1):101-117.e11.|Cell Metab. 2023 Jul 11;35(7):1132-1146.e9.|Cell Physiol Biochem. 2017;44(4):1381-1395.|Cell Physiol Biochem. 2018;51(4):1566-1583.|Cell Rep. 2019 Oct. |Cell Stem Cell. 2024 Jan 4;31(1):52-70.e8.|Dissolut Technol. 2020, 27(1):36-44.|EMBO Rep. 2022 Apr 4;e54147.|Endocrinology. 2018 May 1;159(5):2008-2021.|Exp Mol Med. 2019 May 22;51(5):57. |Front Bioeng Biotechnol. 2022 Mar 17;10:826093.|Front Pharmacol. 2016 Oct 20;7:390.|Front Pharmacol. 2020 Jul 31;11:1038.|iScience. 2023 Jan.|J Biol Chem. 2020 Apr 3;295(14):4451-4463. |J Cell Mol Med. 2017 Dec;21(12):3322-3336.|J Cell Mol Med. 2019 Sep;23(9):6048-6059. |J Neuroinflammation. 2022 Jan 29;19(1):25.|Life Sci. 2019 Sep 1;232:116622.|Mech Ageing Dev. 2020 Oct;191:111347.|Mol Cell Proteomics. 2017 Jul;16(7):1324-1334.|Mol Neurobiol. 2017 Jul;54(5):3327-3341.|Mol Oncol. 2017 Aug;11(8):1035-1049.|Mol Oncol. 2017 Oct;11(10):1475-1492. |Nat Commun. 2019 Feb 6;10(1):620.|Nature. 2023 Sep;621(7977):188-195.|Neuropharmacology. 2020 Mar 15;165:107816.|Onco Targets Ther. 2020 May 4;13:3777-3788. |Patent. US20210128693A1.|Patent. US20240358802A1.|Pathogens. 2021, 10(3), 283.|Pharmaceuticals (Basel). 2024 Sep 19;17(9):1234.|Phytother Res. 2024 May 10.|Redox Biol. 2023 Jun 15, 102786.|Research Square Preprint. 2022 Jan.|Research Square Preprint. 2023 Jul 24.|Signal Transduct Target Ther. 2020 May 20;5(1):56.|Signal Transduct Target Ther. 2023 Mar 6;8(1):95.|Spine (Phila Pa 1976). 2019 Aug 1;44(15):E865-E872. |Transl Stroke Res. 2022 Jul 19.|Virus Res. 2023 Jun 7;333:199139.|Acta Pharmacol Sin. 2021 Sep 3.|Am J Physiol Cell Physiol. 2024 Apr 8.|Ann Transl Med. 2021 Oct;9(20):1547.|Antioxidants. 2020 Oct 28;9(11):1057.|Aquaculture. 2024 Dec 15.|Arch Biochem Biophys. 2022 Jun 15;722:109216.|Biochem Bioph Res Co. 2020 Dec 17;533(4):665-671.|Biochem Cell Biol. 2023 Aug 21.|Biochem Pharmacol. 2023 Jun 6, 115636.|Biofactors. 2023 Mar 16.|Biomolecules. 2022 Mar 9;12(3):422.|bioRxiv. 2023 May 12.|Brain Behav Immun. 2024 Jun 6:S0889-1591(24)00445-8.|Cancer Cell Int. 2024 Feb 14;24(1):74.|Cancer Lett. 2022 Feb 2;215582.|Cancer Lett. 2024 Aug 21:217177.|Cancer Lett. 2024 Feb 13:216732.|Cell Commun Signal. 2023 May 4;21(1):99.|Cell Death Differ. 2023 Jun 19.|Cell Death Dis. 2022 Apr 20;13(4):384.|Cell Mol Life Sci. 2023 Sep 9;80(10):283.|Cell Regen. 2022 May 5;11(1):19.|Cell Rep. 2022 Nov 22;41(8):111707.|Cell Res. 2023 Jul 17.|Cell Signal. 2024 Mar 1:111125.|Circulation. 2022 Nov 30.|Clinical Cancer Drugs. 2020 Apr.|Emerg Microbes Infect. 2022 Feb 22;1-34.|Environ Toxicol. 2021 Aug 25.|Environ Toxicol. 2024 Jan 22.|Eur J Pharmacol. 2023 Aug 1;175942.|Eur J Pharmacol. 2023 Feb 3;943:175569.|Front Immunol. 2016 Dec 12;7:597. |Front Oncol. 2021 Nov 22;11:762523.|Genes (Basel). 2022 Dec 16;13(12):2384.|Hum Reprod. 2020 May 1;35(5):1145-1158.|Int Immunopharmacol. 2023 Sep 15;124(Pt A):110905.|Int J Mol Sci. 2023, 24(1), 343.|Int J Morphol. 40(5):1152-1164, 2022.|J Adv Res. 2024 Apr 14:S2090-1232(24)00155-3.|J Inflamm (Lond). 2024 Jul 9;21(1):25.|J Med Chem. 2022 Aug 29.|J Orthop Surg Res. 2023 Nov 4;18(1):831.|Liver Int. 2023 May 19.|Mol Cell Endocrinol. 2023 Dec 24:582:112140.|Mol Med Rep. 2023 Jan;27(1):17.|Mol Reprod Dev. 2024 Aug;91(8):e23768.|Nat Commun. 2021 Aug 24;12(1):5106.|Onco Targets Ther. 2020 May 19;13:4445-4455.|Oncol Lett. 2021 Jan;21(1):31.|Oral Dis. 2024 Jul 22.|Phytomedicine. 2024 Apr 24:129:155679.|PLoS One. 2023 May 18;18(5):e0283943.|PLoS Pathog. 2023 Feb 3;19(2):e1011126.|PLoS Pathog. 2024 Jun 21;20(6):e1012305.|Protein Cell. 2022 Feb 26.|Res Sq. 2024 Jul 12.|Research Square Preprint. 2020 Dec.|Research Square Print. 2022 Aug.|Research Square Print. November 29th, 2022.|Rheumatology. 2022 Aug 19;keac467.|Sci Total Environ. 2023 Dec 21:912:169496.|Small Methods. 2020, 2000483.|SSRN. 2023 Feb 27.|SSRN. 2024 May 30.|Stem Cells Dev. 2021 Sep 5.|Virus Genes. 2022 Mar 7.Shipping Conditions:
Room TemperatureClinical Information:
LaunchedCAS Number:
1115-70-4